Skip to main content
Skip to main navigation menu
Skip to site footer
Open Menu
Home
Current
Archives
Manuscript Submission
Announcements
Editorial Review Board
Permissions and Licensing
Subscription Information
Advertising Information
Library Referral Form
Library Referral Form - Online
Reprints
The Future of Opioids
Special Issue on Buprenorphine
Special on Legal and Regulatory Aspects of Opioids
Webinars
BUPE2024
User License Agreement
Call for Papers - Updated
About
About the Journal
Editorial Team
Privacy Statement
Contact
Search
Register
Login
Home
/
Archives
/
Vol. 13 No. 6 (2017): November/December - Abuse Deterrent Opioids Special Issue
Vol. 13 No. 6 (2017): November/December - Abuse Deterrent Opioids Special Issue
Published:
11/01/2017
Editorial
From the editor
Paul A. Sloan, MD
349
PDF
From the publisher
Richard A. DeVito, Jr
350
PDF
Doctor driven problem or doctor driven solution?
Lynn R. Webster, MD, FACPM, FASAM
351-352
PDF
Abuse-deterrent formulations of opioids: Many questions still to answer
Raeford E. Brown Jr, MD, FAAP
353-356
PDF
Abuse-deterrent formulations approval reform: Will clinical correctness or real-world results be used to address the nation's opioid crisis: “Noninterference” as a new approval standard
Dan Cohen, MA/LS
357-362
PDF
Letters to the Editor
Opioid overdose protection: An inevitable need to address an alarming epidemic
Beatrice Setnik, PhD
363-364
PDF
Articles
Do abuse deterrent opioid formulations work?
Richard C. Dart, MD, PhD, Janetta L. Iwanicki, MD, Nabarun Dasgupta, PhD, Theodore J. Cicero, PhD, Sidney H. Schnoll, MD, PhD
365-378
PDF
Insights and issues from FDA Advisory Committee meetings on abuse-deterrent opioids
Christopher J. Miller, MS, Richard C. Dart, MD, Nathaniel P. Katz, MD, MS, Lynn R. Webster, MD, FACPM, FASAM
379-389
PDF
Reality and responsibility revisited: Stakeholder accountability in the effort to develop safer opioids
Steven D. Passik, PhD, Howard A. Heit, MD, Michael DeGeorge, PharmD
391-396
PDF
Opioids with abuse-deterrent properties: A regulatory and technological overview
J. David Haddox, DDS, MD
397-413
Requires Subscription or Fee
PDF
(USD 56)
Interpreting labels of abuse-deterrent opioid analgesics
Lynn R. Webster, MD, FACPM, FASAM
415-423
Requires Subscription or Fee
PDF
(USD 56)
Abuse of reformulated OxyContin: Updated findings from a sentinel surveillance sample of individuals assessed for substance use disorder
Theresa A. Cassidy, MPH, Eileen Thorley, MPH, Ryan A. Black, PhD, Angela DeVeaugh-Geiss, PhD, Stephen F. Butler, PhD, Paul Coplan, ScD
425-440
Requires Subscription or Fee
PDF
(USD 56)
Laboratory-based testing to evaluate abuse-deterrent formulations and satisfy the Food and Drug Administration's recommendation for Category 1 Testing
Christopher Altomare, BS, Eric R. Kinzler, PhD, August R. Buchhalter, PhD, Edward J. Cone, PhD, Anthony Costantino, PhD
441-448
Requires Subscription or Fee
PDF
(USD 56)
Intranasal abuse potential of an abuse-deterrent oxycodone formulation compared to oxycodone immediate release and placebo in nondependent, recreational opioid users
Beatrice Setnik, PhD, Kerri Schoedel, PhD, Cindy Bartlett, MMath, Chris Dick, MS, MBA, Nasrat Hakim, MS, LLM, Pierre Geoffroy, MDCM, MSc, FCFP, DABAM
449-464
Requires Subscription or Fee
PDF
(USD 56)
Abuse-deterrent features of an extended-release morphine drug product developed using a novel injection-molding technology for oral drug delivery
Nikolaj Skak, MS, Torben Elhauge, MSc, Jeffrey M. Dayno, MD, Karsten Lindhardt, MSc, PhD, DBE
465-472
Requires Subscription or Fee
PDF
(USD 56)
Application of hot-melt extrusion technology in immediate-release abuse-deterrent formulations
Klaus Wening, PhD, Sebastian Schwier, PhD, Hans-J. Stahlberg, MD, Eric Galia, PhD
473-484
Requires Subscription or Fee
PDF
(USD 56)
Review Articles
Evaluating the abuse potential of opioids and abuse-deterrent opioid formulations: A review of clinical study methodology
Beatrice Setnik, PhD, Kerri A. Schoedel, PhD, Naama Levy-Cooperman, PhD, Megan Shram, PhD, Glenn C. Pixton, MS, Carl L. Roland, PharmD, MS
485-523
Requires Subscription or Fee
PDF
(USD 56)
Full Issue
Abuse Deterrent Opioids: Clinical and Public Policy Implications
341-524
Requires Subscription or Fee
PDF
(USD 56)
Old JOM header
ad_block_3
Subscription
Login to access subscriber-only resources.
Make a Submission
Make a Submission
Information
For Readers
For Authors
For Librarians
Keywords
Announcements